Dec 31 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Axsome Therapeutics, Ducommun and Vacasa on Tuesday.
HIGHLIGHTS
* Axsome Therapeutics Inc AXSM.O: Needham raises target price to $133 from $130 |
* Ducommun Inc DCO.N: RBC reinstates coverage with outperform rating |
* Vacasa Inc VCSA.O: Needham cuts to hold from buy |
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order.
* Axsome Therapeutics Inc AXSM.O: Needham raises target price to $133 from $130 |
* Axsome Therapeutics Inc AXSM.O: RBC raises target price to $138 from $132 |
* Cal-Maine Foods Inc CALM.O: Stephens raises target price to $88 from $82 |
* Ducommun Inc DCO.N: RBC reinstates coverage with outperform rating |
* Ducommun Inc DCO.N: RBC reinstates coverage with price target $72 vs $60 |
* Marinus Pharmaceuticals Inc MRNS.O: Baird raises target price to $0.55 from $0.50 |
* Vacasa Inc VCSA.O: Needham cuts to hold from buy |
* Verastem Inc VSTM.O: BTIG raises target price to $20 from $13 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.